Chemotherapy Effect, Susceptibility, Genetic
Conditions
Keywords
breast cancer, neoadjuvant chemotherapy,susceptible gene
Brief summary
We plan to carry out a prospective, randomized, open phase III clinical trial which sponsored by the Tianjin Medical University Cancer Hospital and Institute. The primary aim is to evaluate pCR of DT and ET regimen as neoadjuvant chemotherapy in the treatment of HER2 negative Luminal B breast cancers and the correlation of pCR respectively with the susceptible gene mutation scores and differential protein identified by proteomics. For patients with pCR, the association between the 5 year DFS and susceptible gene mutation scores and differential protein identified by proteomics will be evaluated. All Non-pCR patients will receive NX chemotherapy for 4 cycles, and to evaluate correlations between 5 year DFS of these patients respectively with susceptible gene mutation scores and differential protein identified by proteomics, and to evaluate the safety of neoadjuvant chemotherapy and sequential adjuvant NX regimen therapy. Meanwhile, we will verify susceptible gene mutation scores and differential protein identified by proteomics are significant predictors of HER2 negative Luminal B breast cancer chemotherapy sensitivity and prognosis, and explore the feasibility of susceptible gene mutation scores and differential protein in clinical application.
Detailed description
This is a prospective, randomized, open phase III clinical trial which will be sponsored by the Tianjin Medical University Cancer Hospital and Institute. The primary aim is to evaluate pCR of Pegylated Liposomal Doxorubicin and Docetaxel (DT) Compared to Conventional Doxorubicin and Docetaxel (ET) regimen as neoadjuvant chemotherapy in the treatment of HER2 negative Luminal B breast cancers and the correlation of pCR respectively with the susceptible gene mutation scores and differential protein identified by proteomics. For patients with pCR, the association between the 5 year DFS and susceptible gene mutation scores and differential protein identified by proteomics will be evaluated. All Non-pCR patients will receive NX chemotherapy for 4 cycles, and to evaluate correlations between 5 year DFS of these patients respectively with susceptible gene mutation scores and differential protein identified by proteomics, and to evaluate the safety of neoadjuvant chemotherapy and sequential adjuvant Nalvelbine and Xeloda (NX) regimen therapy. Meanwhile, we will verify susceptible gene mutation scores and differential protein identified by proteomics are significant predictors of HER2 negative Luminal B breast cancer chemotherapy sensitivity and prognosis, and explore the feasibility of susceptible gene mutation scores and differential protein in clinical application.
Interventions
DRUGDT group
Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
DRUGET group
Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
DRUGNX group
Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form * Compliance with test procedures and good compliance * Females, Age more than 18 years of age, less than 70 years old * The ECOG score is 0-1 * Primary invasive cancer, T2-4bN0-2M0 breast cancers * Neoadjuvant chemotherapy with standard 6 courses should be completed * Patients must undergo standard breast cancer surgery after neoadjuvant chemotherapy * Luminal B, Her2 negative patients * No other malignant tumors occurred at the same time * adequate liver and kidney function
Exclusion criteria
* Any metastasis * Suffered other maligant tumors * Participate in other trials * Accompanied with severe systemic disease and / or uncontrollable infection * Pregnant and lactating women * Dysfunction of liver and kidney
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR rate | 2 years | pCR rate in the DT and ET group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of neo-adjuvant chemotherapy | 5 years | 5-year DFS in the DT and ET group |
| Efficacy of sequential chemotherapy | 6 years | 5-year DFS of non- pCR patients treated by sequential NX regimen |
Countries
China
Contacts
Primary ContactSheng Zhang, Doctor
Outcome results
None listed